Endo It is my belief that the next big move will be the announcement that the Phase 3b trial has started. It will probably be another month + for Endo to put its lead team together and bring them up to speed on the previous trials and results to date..Hopefully most of the 30 centers that were involved with the 3a trial will stay on board with a few more Endo friendly centers added. To date Endo's financial involment is pocket change to the large caps..The initiation of the 3b trial will indicate that Endo has the confidence to make the large commitment of time, personnel ,and cash to get Urocidin to market. This release will put Bioniche in the spot light of credibility.
The next quarterly results will also be lifting as I hope that it will be free of 3a trial expenses. I f the animal div. can maintain its momentum we may just see a positive return..Anything positive on the ecoli program would be gravy. Although I doubt it , there may be a small milestone payment with the commencement of the 3b trial. I would think the next milestone is 3a results where cash is tied to end point safety and efficacy.
Its been a long haul for most of us but I believe we will have a good Christmas and 2010. Stay tough...Dusty11